[{"orgOrder":0,"company":"Advent","sponsor":"The Jenner Institute, Oxford University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ITALY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Advent","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Advent Therapeutics Awarded $3 Million NIH Grant for Novel Neonatal Lung Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Advent
The grant will allow the Company to position its novel aerosolized retinol palmitate (vitamin A) formulation for commercialization in 2025 to prevent Bronchopulmonary Dysplasia (BPD).
The Jenner Institute at the University of Oxford has agreed a contract with Advent Srl, to produce the first batch of the novel coronavirus vaccine ChAdOx1 nCoV-19 for clinical testing.